Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Polynovo ( (AU:PNV) ) has provided an announcement.
PolyNovo has reported a strong financial year with significant growth in commercial sales and regulatory clearances, expanding its market reach to 46 countries. The company is poised for further growth with the upcoming commercialization of new products and anticipated pricing reforms, supported by a robust cash position and strategic leadership changes.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a company operating in the medical device industry, primarily focusing on the development and commercialization of NovoSorb products for complex wound management. The company has expanded its market presence to 46 countries and is known for its innovative solutions in the field of wound care.
Average Trading Volume: 3,547,644
Technical Sentiment Signal: Sell
Current Market Cap: A$894.6M
For a thorough assessment of PNV stock, go to TipRanks’ Stock Analysis page.